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Abstract 
Carcinoembryonic antigen-related cell adhesion molecule-2 (CEACAM2) is a cell 
surface glycoprotein expressed on blood, epithelial and vascular cells. CEACAM2 
possesses adhesive and signaling properties mediated by immunoreceptor tyrosine-
based inhibitory motifs. In this study, we demonstrate that CEACAM2 is expressed 
on the surface and in intracellular pools of platelets. Functional studies of platelets 
from Ceacam2
–/–
 deficient mice (Cc2
–/–
) revealed that CEACAM2 serves to 
negatively regulate collagen GPVI-FcRγ–chain and the C-type lectin-like receptor 2 
(CLEC-2) signaling. Cc2
–/–
 platelets displayed enhanced GPVI and CLEC-2-
selective ligands, collagen related peptide (CRP), collagen and rhodocytin (Rhod)-
mediated platelet aggregation.  They also exhibited increased adhesion on type I 
collagen, and hyper-responsive CRP and CLEC-2-induced alpha and dense granule 
release compared to wild-type platelets. Furthermore, using intravital microscopy to 
ferric chloride (FeCl3) injured mesenteric arterioles and laser induced injury of 
cremaster muscle arterioles, we herein show that thrombi formed in Cc2
–/– 
mice 
were larger and more stable than wild-type controls in vivo. Thus, CEACAM2 is a 
novel platelet immunoreceptor that acts as a negative regulator of platelet GPVI-
collagen interactions and of ITAM receptor CLEC-2 pathways. 
 
Key Points:  
CEACAM2 is a novel platelet immunoreceptor. 
CEACAM2 negatively regulates platelet:collagen interactions and thrombus growth 
and stability in vitro and in vivo as well as the CLEC-2 activation pathways. 
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Introduction 
Many negative regulatory mechanisms down-modulate in vivo platelet-collagen 
interactions. Major regulators include nitric oxide and prostacyclin [1], expressed by 
the endothelium, and members of the immunoglobulin (Ig) immunoreceptor 
tyrosine-based inhibitory motif (ITIM) superfamily, contained within platelets. The 
latter group includes platelet endothelial cell adhesion molecule–1 (PECAM-1), and 
carcinoembryonic antigen-related cell adhesion molecule–1 (CEACAM1), which 
auto-regulate platelet interactions in the presence of collagen [2-5]. Collagen plays a 
role in platelet adhesion and thrombus development, especially with glycoprotein–
VI (GPVI)/Fc receptor (FcR)γ–chain signaling. Thus, natural inhibitors of the auto-
regulatory mechanisms moderating signaling processes between the GPVI/FcRγ–
chain and collagen must be present in platelets.  
The ITIM-bearing receptor regulation of immunoreceptor tyrosine-based 
activation motif (ITAM) in leukocytes is well understood. However, less is known 
about regulation in platelets where Ig-ITIM–bearing receptors bind with multiple 
phosphatase types, including SH2-containing tyrosine phosphatase-1 and -2 (SHP-1, 
SHP-2), and SH2 domain-containing inositol polyphosphate 5’-phosphatase (SHIP) 
[6]. Current theories suggest that Ig-ITIM bearing receptors undergo differential 
interaction with distinct phosphatase groups, in a manner depending on cell 
conditions and activation status [7, 8]. 
Regulation of these complex inhibitory mechanisms is difficult to dissect out 
because, under certain conditions, inhibitory ITAM signaling is mediated by ITAM-
bearing receptors, via the FcRγ–chain or DAP12 adaptor [9, 10]. Switching between 
ITAM signaling activation and inhibition is governed by the strength of ligand 
binding to the receptor. Low-avidity ligand interactions may influence regulation of 
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inhibitory signaling by phosphatases. Conversely, higher-avidity ligand cross 
linkages may activate ITAM-mediated signaling responses. Hence, understanding 
the complex relationship between activation and inhibition in platelets is crucial [9, 
10]. 
In murine platelets, there are two hemi ITAM associated signaling pathways, 
collagen GPVI-FcR–chain and the C-type lectin-like receptor 2 (CLEC-2).  The 
snake venom protein rhodocytin is a CLEC-2 ligand that induces CLEC-2 clustering 
and platelet activation. CLEC-2 receptor induces activation-dependent signaling 
through a similar GPVI-FcR–chain pathway.  However, CLEC-2 signals relies 
more on Syk rather than Src tyrosine kinases and the PLCγ2-dependent mechanism 
of platelet activation [11, 12]. 
Several studies imply that Ig-ITIM superfamily members in platelets regulate 
platelet-collagen interactions. Human and murine platelets do not contain the 
prototypic inhibitory Ig-ITIM superfamily member FcγRIIb, but instead, PECAM-1 
and CEACAM1 Ig-ITIM-superfamily members capable of negatively regulating 
platelet interactions with collagen [2, 3, 13]. Other Ig-ITIM superfamily members, 
including triggering receptors expressed on myeloid cells (TREM), transcript-1 
(TLT-1), and G6B, are critical for modulating platelet function [14, 15]. Much 
remains to be investigated in order to assess the contribution of Ig-ITIM superfamily 
in platelet thrombus formation. 
CEACAM2 (previously known as Bgp2) is a type I-transmembrane receptor from the 
CEACAM superfamily of genes that is expressed in few cell types, including intestinal 
tissue crypt epithelia, kidney cells, testis and several nuclei in the brain, including the 
ventromedial hypothalamus [16-18]. CEACAM1 and CEACAM2 proteins, encoded by 
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different genes containing 9 exons each [19], share a similar overall structure in particular 
with respect to Ig-Domains in the extracellular segment and an almost identical ITIM-
containing cytoplasmic tail. However, the two proteins differ by two important features. 
Firstly, CEACAM1 predominantly possesses four extracellular Ig-Domains (CEACAM1-
4L), in contrast to CEACAM2 that has two extracellular Ig-Domains (N terminal, A2 
domain) resulting from alternative splicing of exons 3 and 4 (CEACAM2-2L) [18].  This 
leads to a differential degree of glycosylation with CEACAM2 containing 5 out of the 16 N-
linked glycans in CEACAM1. Secondly, the two receptors display differential ligand 
binding properties of the distal variable N-terminal Ig-Domain that promotes homophilic 
binding in CEACAM1, but not CEACAM2 [20].  The only ligand thus far identified for 
CEACAM2 is the murine coronavirus mouse hepatitis virus spike glycoprotein (s). In 
addition, CEACAM proteins utilize two ITIMs to recruit SHP-1, and to a lesser degree, 
SHP-2 protein-tyrosine phosphatase [21, 22]. With SHP-1 playing an important role in 
platelet activation by the collagen receptor glycoprotein VI [23], it is likely that SHP 
recruitment to the ITIM domains of CEACAM1 contributes to the regulatory role of 
CEACAM1 in platelet-collagen interaction [13]. 
Potential involvement of CEACAM2 in regulating platelet-collagen interactions, CLEC-2 
signaling and thrombus formation is poorly understood. Thus, the current studies 
investigated whether CEACAM2 regulates platelet-collagen interactions, both in vitro and 
in vivo, as well as CLEC-2 dependent pathways.  
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Materials and Methods 
Antibodies and Chemicals  
The specific rabbit anti–mouse CEACAM2 polyclonal antibody (2052) [16] and 
CEACAM1 antibody (2457) [13, 24] were previously described. PECAM-1 
antibody (Anti-mouse, 390) was provided by Dr Steve Albelda (Philadelphia, PA) 
[25]. Anti-rabbit fluorescein isothiocyanate (FITC) and rabbit anti-mouse 
phycoerythrin (PE) were purchased from Dako (Botany, Australia). Anti-mouse 
GPVI [26], anti-mouse integrin α2β1 (CD49b) [27], anti-mouse GPIbα-IX-V 
complex (CD42b) [28], and anti-mouse GPVI (JAQ1) [29] were purchased from 
Emfret Analytics (Würzburg, Germany). Anti-mouse integrin αIIbβ3 (CD61) [30],
 
anti-mouse CD44 [31], isotype control antibody CD3e and horseradish peroxidase 
(HRP)-conjugated antiphosphotyrosine-RC20 antibodies were obtained from BD 
Biosciences Pharmingen (Franklin Lakes, NJ). Antiphosphotyrosine 4G10 antibody 
was from Millipore (Billerica, MA). Rabbit anti-Akt-(#9272), anti-phospho-Akt-
(S473, #4060), anti-phospho-Src-(Tyr416) and anti-Src-(36D10) antibodies were 
purchased from Cell Signaling Technology (Danves, MA). Anti-mouse CD9 [32], 
PLCγ2 (sc-407), Syk (c-20; sc-929), ERK-2 and GAPDH-(sc-32233) antibodies 
were purchased from Santa Cruz Biotechnology (Dallas, TX).  Rhodocytin snake 
venom protein was kindly donated by Professor Bernard Nieswandt (Ruldolf 
Virchow Center, Germany). 
Mice 
The generation of Cc2
–/–
 mice and breeding onto C57BL/6 background for 10 
generations has been described [16].
 
Wild-type C57BL/6 mice were purchased from 
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ARC animal facility, Perth, WA. Age- and sex-matched wild-type and Cc2
–/–
 
littermates were housed at RMIT University animal facility. All procedures were 
approved by the RMIT University animal ethics committee #0918 and #1239. 
Hematological parameters 
Hematological parameters were determined on EDTA samples collected from wild-
type and Cc2
–/–
 mice using an Emerald hematology analyzer (Abbott, Illinois, USA). 
100 white blood cell differentials were performed and expressed as percentage and 
absolute count (x10
9
/L). 
Platelet preparation 
Platelet-rich plasma (PRP) and washed murine platelets were isolated as previously 
described [33]. 
Platelet aggregation 
Platelet aggregation responses were measured on a 4-channel light transmission 
aggregometer as previously described [34, 35].
 
 
Flow Cytometry 
Surface and total expression of CEACAM2 in wild-type and Cc2
–/–
 platelets was 
performed using washed platelets, for total expression, platelets were resuspended in 
0.1% (w/v) saponin as previously described [13, 36], and rabbit anti-mouse 
CEACAM2 antibody, 2052 (1/100). 
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Dense granule release using quinacrine uptake 
Dense granule release was performed as previously described [2]. Dense granule 
exocytosis was recorded as the percentage decrease in quinacrine fluorescence 
intensity compared to resting platelets. 10,000 individual platelets were analyzed on 
a FACS Canto II flow cytometer and by Weasel software Version 3.0.2. 
Static platelet adhesion on type I collagen 
A time course of static platelet adhesion was performed for wild-type and Cc2
–/–
 
platelets as previously described [34].  
Immunoprecipitation and immunoblotting 
Immunoprecipitation and immunoblotting were performed as previously described 
[2, 17]. 
In vivo thrombosis models 
Ferric chloride-induced injury of mesenteric arterioles (80-100 µm) [13], laser 
induced injury of cremaster muscle arterioles
 
(30-40 µm) [37, 38] and GPVI 
depletion
 
using JAQ1 antibody [29] were performed as previously described. 
Analysis of murine platelet adhesion and thrombus formation under in vitro 
arterial flow 
A three channel µ-slide III
0.1 
with dimensions (0.1 x 1.0 x 45 mm, H x W x L), 
(microslides, ibidi, Martinsried, Germany) were coated with 500 µg/mL type I 
fibrillar collagen (Nycomed) for 1 hour at 37
o
C. Whole blood from wild-type and 
Cc2
–/–
 mice was normalized to 3x10
8
/mL platelets then incubated with 0.05% (w/v) 
Rhodamine 6G dye for 30 minutes at 37
o
C. Labeled whole blood was perfused 
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through the collagen-coated µ-slide-III
0.1
 at a shear wall flow rate of 1800 seconds
-1
 
for four minutes. Non-adherent cells were removed by the flow of Ringer-Citrate-
dextrose (RCD) buffer pH 7.4 at the same shear wall flow rate. Thrombi were 
recorded in real-time using Z-stack analysis and deconvolution of 3D 
reconstructions using a Zeiss Axiovert microscope and Axiovision Rel4.6 software. 
Thrombus volume was calculated from the thrombus area (µm
2
) multiplied by the 
thrombus height (µm) for wild-type and Cc2
–/–
 at various time points.  
Statistical
 
analysis 
Data were checked for normal distribution
 
using the Shapiro-Wilks normality test 
and statistical significance was determined using unpaired student’s t test and two-
way analysis of variance (ANOVA). P values below 0.05 were considered 
significant. Data were analyzed by using GraphPad Prism software program version 
5 (GraphPad, San Diego, CA). 
 
 
 
 
 
 
 
 
 
9 
 
Results 
Ceacam2-null mice have normal hematopoiesis parameters 
To determine whether Ceacam2 deletion affects production of hematopoietic cells 
such as platelets, cells from sex- and age-matched wild-type and Cc2
–/–
 mice were 
compared. As Table 1 reveals, all hematological parameters including hemoglobin 
(Hb) as well as white blood cell (WBC), red blood cell (RBC), and platelet count 
were normal in Cc2
–/–
 compared to wild-type mice (P>0.05; n=6). 
CEACAM2 is expressed on the surface and in the intracellular pool of murine 
platelets 
Next, we investigated the cellular compartmentalization of CEACAM2 in resting 
murine platelets. To determine whether CEACAM2 is expressed at the surface 
membrane and whether this is increased after granule release, we examined the 
binding of a specific anti–mouse CEACAM2 polyclonal antibody to resting and 
agonist-stimulated wild-type mouse platelets, detected by flow cytometry. As 
shown in Figure 1A, resting platelets incubated with the anti-mouse CEACAM2 
antibody exhibited a two-fold increase in surface expression compared to normal 
rabbit pre-immune serum (21.56±1.754 vs 9.854±1.597, respectively; **P<0.01; 
n=5). This finding indicates the presence of CEACAM2 on the surface of mouse 
platelets. In addition, characterization of the total distribution of CEACAM2 in 
mouse platelets was determined by permeability of the platelet membrane with 
saponin. Saponin-treated platelets incubated with anti-CEACAM2 antibody 
exhibited a 2.5-fold higher mean fluorescence intensity (MFI) than those 
incubated with normal rabbit pre-immune serum (83.66±8.935 vs 33.08±6.756, 
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respectively; **P<0.01; n=5; Figure 1A). This finding points to an additional 
intracellular CEACAM2 pool in murine platelets. CEACAM2 is pre-dominantly 
expressed in platelets as the commonly found CEACAM2-2L (CC2-2L) form of 
~ 52 kDa (Figure 1C). CC2-2L of CEACAM2 contains 2 Ig-Domains (N 
terminal, A2 domain), a transmembrane domain and long ITIM-containing 
cytoplasmic domain. Cell surface expression of CEACAM2 was increased in a 
dose responsive manner upon agonist stimulation with thrombin, protease 
activated receptor-4 agonist peptide (PAR-4) and collagen-related peptide (CRP) 
compared to resting platelets (***P<0.001; n=4; Figure 1B). Whereas 
CEACAM2 was absent in Cc2
–/–
 platelets (Figure 1D), the expression of several 
platelet glycoproteins, including GPVI, PECAM-1, CEACAM1, integrin α2β1, 
integrin αIIbβ3, GPIb-IX-V complex, CD44 and CD9 was similar to that in wild-
type platelets (Figure 1D-F). Consistently, up-regulation of CEACAM1 surface 
expression was similar in wild-type and Cc2
–/–
 platelets in a dose-dependent 
manner in response to thrombin, PAR-4 agonist peptide and CRP (Figure 1G). 
These data show that CEACAM2 is localized to both the surface and the 
intracellular pool in resting murine platelets. 
Ceacam2-null platelets are hyper-responsive to GPVI and CLEC-2-selective 
agonists 
Next, we examined whether CEACAM2 negatively regulates ITAM-bearing, 
collagen–GPVI and CLEC-2–mediated platelet response. To this end, wild-type and 
Cc2
–/– 
platelets were stimulated using a range of G-protein–coupled agonists (PAR-4 
agonist peptide; 100–300 µM; Figure 2A.a–c), adenosine diphosphate (ADP; 2.5–10 
µM; Figure 2A.d–f) and calcium ionophore (CI-A23187; 1.25–5.0 µg/mL; Figure 
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2A.g–i), with acid-soluble type I collagen (1.5–4 µg/mL; Figure 2A.j–l), the GPVI 
collagen receptor selective agonist, CRP (0.62–2.5 µg/mL; Figure 2A.m–o) and the 
CLEC-2 receptor agonist, Rohd (0.12-0.48 µg/mL; Figure 2A.p–r). As shown in 
Figure 2A-B, similar platelet aggregation profiles were observed in wild-type and 
Cc2
–/– 
platelets treated with PAR-4 agonist peptide, ADP and CI. However, in 
response to collagen, CRP and Rhod agonist, stimulation of platelet aggregation was 
observed in Cc2
–/– 
platelets, particularly at sub-threshold doses compared to wild-
type platelets. These data suggest that lack of CEACAM2 leads to hyper-responsive 
tyrosine-kinase dependent signaling pathway in platelets upon collagen, CRP and 
Rhod stimulation. 
Ceacam2-null
 
platelets demonstrate enhanced alpha and dense granule 
secretion   
As Cc2
–/–
 platelets exhibited hyper-responsive GPVI- or CLEC-2-mediated platelet 
aggregation responses, we investigated whether lack of CEACAM2 affects the 
platelet-release reaction stimulated by GPVI-specific agonist, CRP. The ability of 
wild-type and Cc2
–/–
 platelets to secrete alpha (P-selectin) and dense granule 
(Quinacrine) upon GPVI and CLEC-2 stimulation was determined. As seen in 
Figure 3A–B, Cc2–/– platelets released more alpha and dense granules at all doses of 
CRP and Rhod compared with wild-type platelets, but not when treated with 
thrombin and PAR-4 agonist peptide at any dose (*P<0.05; **P<0.01; ***P<0.001; 
n=4). Interestingly, Cc2
–/–
 platelets released similar alpha granules upon CRP 
stimulation as compared to Cc1
–/–
 platelets (Figure 3A.b). Moreover, Cc2
–/–
 platelets 
released similar alpha and dense granules upon Rhod stimulation as compared to 
Cc1
–/–
 platelets (Figure 3A.c–B.c). These results support the hypothesis that 
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CEACAM2 acts as a negative regulator of GPVI and CLEC-2–mediated platelet 
granule release. 
Ceacam2-null
 
platelets display increased static adhesion to immobilized type I 
fibrillar collagen 
We examined whether CEACAM2 modulates collagen–GPVI–mediated platelet 
response in a manner similar to other platelet immunoreceptors. Static platelet 
adhesion on type I fibrillar collagen was performed to determine the binding 
characteristics of platelets derived from wild-type and Cc2
–/–
 mice over time. 
Ceacam2-null platelets bound more to immobilized type I fibrillar collagen but not 
negative control (RCD buffer) compared to wild-type platelets at all time points 
(*P<0.05, **P<0.01; ***P<0.001; n=3; Figure 4). Together, this reveals that upon 
static adhesion to immobilized type I collagen, Cc2
–/–
 platelets exhibited a hyper-
responsive platelet adhesion compared to wild-type platelets. 
Tyrosine phosphorylation including PLCγ2, Src and Syk is enhanced in Cc2–/– 
platelets after CRP stimulation and PLCγ2, Syk after Rhod stimulation  
To determine whether CEACAM2 plays a negative regulatory role in ITAM 
signaling pathways in platelets, wild-type and Cc2
–/–
 platelets were stimulated using 
10 µg/mL of CRP over a 3 minute-period. Global tyrosine phosphorylation of 
proteins in platelets derived from CRP-stimulated Cc2
–/– 
and wild-type mice was 
measured. Several tyrosine hyper-phosphorylated proteins of 54, 56, 65, 71, 74, 83 
and 93kDa apparent molecular mass were detected in Cc2
–/–
 in response to CRP 
stimulation for 15 seconds - 3 minutes by comparison to wild-type platelets (Figure 
5A). Furthermore, PLCγ2, Src and Syk tyrosine phosphorylation was measured after 
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CRP and Rhod-stimulation for 0-90 seconds by immunoprecipitation and Western 
blot analysis with phosphotyrosine antibodies. As shown in Figure 5B, CRP-
stimulated Cc2
–/–
 platelets showed a 5-fold increase in PLCγ2 tyrosine 
phosphorylation (0.5230±0.014 vs 0.1340±0.004; ***P<0.001; n=3; Figure 5B.a), a 
3-fold increase in Src tyrosine phosphorylation (0.4573±0.051 vs 0.2710±0.027; 
*P<0.05; n=3; Figure 5B.b), and a 3.5-fold increase in Syk tyrosine phosphorylation 
(0.5437±0.011 vs 0.1167±0.008; ***P<0.001; n=3; Figure 5B.c) compared to wild-
type platelets. In addition, PLCγ2 and Syk tyrosine phosphorylation was measured 
after Rhod-stimulation for 0–90 seconds. As shown in Figure 5C, Rhod-stimulated, 
Cc2
–/–
 platelets showed a 3.5-fold increase in PLCγ2 tyrosine phosphorylation 
(0.4063±0.014 vs 0.1093±0.034; **P<0.01; n=3; Figure 5C.a), and a 3-fold increase 
in Syk tyrosine phosphorylation (0.4050±0.060 vs 0.1508±0.029; **P<0.01; n=3; 
Figure 5C.b), in the presence of equivalent PLCγ2, Src and Syk, and ERK-2 
antigens (bottom panel) compared to wild-type platelets. These data are consistent 
with CEACAM2 playing a role in attenuating platelet GPVI–collagen interactions 
and the CLEC-2 ITAM signaling pathway.  
CEACAM2 regulation of platelet thrombus formation is dependent on platelet–
collagen interactions under arterial flow in vitro 
As Cc2
–/–
 platelets displayed strong adhesion on immobilized type I collagen, in 
vitro flow studies were performed to determine the functional role of CEACAM2 in 
modulating platelet thrombus formation. Rhodamine-labeled whole blood from both 
wild-type and Cc2
–/–
 mice was perfused onto immobilized type I fibrillar collagen at 
arterial shear rate of 1800 seconds
-1
. After four minutes of blood perfusion, thrombi 
images were recorded in real-time for wild-type and Cc2
–/–
 platelets (Figure 6A). Z-
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stacks were deconvolved and parameters of thrombus area, height and volume were 
determined. Cc2
–/–
 platelets exhibited a significant increase in thrombus area 
compared to wild-type platelets (2303±470.6 vs 907.2±87.26 µm
2
; ***P<0.001; 
n=10; Figure not shown). Similarly, Cc2
–/–
 platelets showed increased kinetics 
thrombus volume over time compared to wild-type platelets (30480±3822 vs 
12480±588.2 µm
3
; ***P<0.001; n=10; Figure 6B). As Cc2
–/–
 females are obese and 
insulin resistant [16] and Cc2
–/–
 males are lean and insulin sensitive [17] and platelet 
activation is associated with diabetes, we sex-stratified the in vitro thrombus 
formation to investigate a potential sexual dimorphic effect. Cc2
–/–
 platelets showed 
increased thrombus volume in both male and female mice compared to wild-type 
platelets (*P<0.05; Figure 6C). Collectively, platelet adhesion onto immobilized 
type I collagen under arterial flow demonstrated that CEACAM2 is important in 
regulating platelet thrombus formation in vitro under flow. 
CEACAM2 acts as a negative regulator of platelet thrombus formation in vivo 
The Ig-ITIM superfamily members, PECAM-1 and CEACAM1, negatively regulate 
platelet GPVI-collagen interactions and thrombus growth, in vitro and in vivo [2, 
13]. Thus, we tested whether CEACAM2 plays a similar role in platelet thrombus 
formation in vivo. We utilized the FeCl3 vascular injury model of mesenteric 
arterioles and laser-induced vascular injury of cremaster arterioles for wild-type 
versus Cc2
–/–
 mice. We observed thrombus growth characteristics by measuring 
fluorescently labeled platelets bound at injury sites. 
Cc2
–/–
 arterioles showed increased thrombus growth and stability over a ten-
minute period, and they had a larger surface coverage of platelets (thrombus area) 
than wild-type arterioles (Figure 7A.a). Furthermore, thrombus volume in Cc2
–/–
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arterioles was significantly larger (166900±7601 vs 120500±2390 µm
3
; 
***P<0.0001; n=30; Figure 7A.b-c), and the stability score of thrombi formed in 
Cc2
–/–
 arterioles was higher than in wild-type arterioles (7.267±0.143 vs 
3.493±0.136; ***P<0.0001; n=30; Figure 7A.d). Cc2
–/–
 arterioles showed no 
difference in the time to first thrombus larger than 20 µm
2
, and time to vessel 
occlusion (P > 0.05; n=30; data not shown), when compared to wild-type arterioles. 
Typically, following laser-induced vascular injury of cremaster arterioles, Cc2
–/–
 and 
Cc1
–/– 
arterioles had greater thrombus volume compared to wild-type arterioles 
(37355±702.6 vs 31956±785.1 vs 15578±543.7, respectively; ***P<0.0001; n=30; 
Figure 7B.a), and they were more stable (5.733±0.143 vs 4.80±0.010 vs 
2.967±0.0894, respectively; ***P<0.0001; n=30; Figure 7B.b). 
As GPVI collagen receptors interact directly with type I collagen during 
thrombus formation, GPVI was depleted in vivo for five days prior to FeCl3 injury 
treatment with the GPVI neutralizing antibody, JAQ1 (100 µg/mouse) [29]. GPVI 
depletion was confirmed using Western blotting of wild-type and Cc2
–/–
 platelet 
lysates (data not shown). Different cohorts of wild-type and Cc2
–/–
 mice were treated 
with negative isotype control IgG (100 µg/mouse). Compared to wild-type, isotype-
treated or untreated wild-type arterioles, JAQ1-treated Cc2
–/–
 arterioles displayed 
significant differences for a two-fold reduction in thrombus volume and stability 
score (***P<0.001; n=10; Figure 7C.a). Importantly, upon JAQ1 treatment, Cc2
–/–
 
arterioles displayed reversal of the increased thrombus stability and growth 
phenotype compared to wild-type arterioles (***P<0.001; n=10; Figure 7C.b). In 
general, these results suggest that CEACAM2, in tandem with GPVI, contributes to 
the more stable thrombus phenotype. 
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Discussion 
Maintaining platelet quiescence requires a balance between activation and inhibition 
signaling events mediated by ITAM and regulated by ITIM-bearing receptor 
signaling. Healthy arterial endothelium is able to provide powerful inhibitory 
signaling to platelets via release of bioactive nitrous oxide (NO) and prostaglandin I2 
(PGI2). However, upon endothelial damage or disease, where bioactive NO and PGI2 
concentrations are low, collectively platelet ITIM-bearing receptors play an 
important role as negative regulators [1]. In addition, like in the immune system a 
homeostatic balance is required between activation and inhibition and this is 
provided in platelets through ITAM and ITIM bearing receptor pathways [1]. This 
stimulates the activation mechanisms to produce pathological thrombus formation. 
Under these circumstances, platelets may provide the inhibitory signaling mediated 
via cell contact events. Platelets contain at least 4 ITIM-bearing receptors, PECAM-
1, CEACAM1, G6B, and TREM-like transcript 1 [2, 3, 13-15, 39]. While 
individually, these exert moderate inhibition of collagen and thrombin signaling in 
platelets, collectively they regulate the cell contact signaling events involved in the 
initiation of platelet thrombus formation in order to limit occlusive pathological 
thrombi.   
To our knowledge, this study provides the first report of a new ITIM-bearing 
receptor, CEACAM2 in murine platelets. The key findings in this study is that 
CEACAM2 is expressed as the CC2-2L form in platelets (Figure 1C), similar to 
other cell types such as ventromedial hypothalamus [16] and spermatids [18]. 
Moreover, CEACAM2 is expressed on the surface as well as in the intracellular pool 
of resting platelets (Figure 1A). In vitro data show that CEACAM2 can negatively 
regulate the collagen GPVI and CLEC-2 ITAM-signaling pathway in platelets. 
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Under in vitro conditions of physiological arterial shear flow, absence of 
CEACAM2 results in increased surface coverage of platelets on immobilized type I 
collagen (Figure 6A). There was no evidence of sexual dimorphism with regard to 
this enhanced thrombus growth phenotype of Cc2
–/–
 platelets. In addition, using 
several models of microvascular thrombosis in vivo, we show that Ceacam2 deletion 
results in larger and more stable thrombi than wild-type mice, and that this is at least 
partly, depends on the presence of GPVI (Figure 7). Collectively, these findings of 
the initial characterization of CEACAM2 in murine platelets and its ability to 
negatively regulate platelet-collagen interactions in vitro and in vivo are reminiscent 
of the functions of the other related ITIM-bearing receptor, CEACAM1. These two 
receptors share similarities in structure and function in many biological systems, 
particularly in their ability to act as inhibitory co-receptors to modulate ITAM-
associated signaling pathways. Essentially, Cc1
–/–
 and Cc2
–/–
 have similar 
phenotypes in platelet GPVI-collagen interactions and CLEC-2 interactions. 
Moreover, Ceacam2 deletion was associated with CRP- and Rhod-stimulated 
platelets producing tyrosine hyper-phosphorylation of PLC-2, Src and Syk; all 
components upstream and downstream of either GPVI or CLEC-2 ITAM-associated 
signaling pathways (Figure 5B-C). This would be consistent with CEACAM2 acting 
as an ITIM-bearing receptor in platelets to down-modulate ITAM-associated 
signaling, similarly to CEACAM1 the ITIM-containing tail of which is almost 
identical to that of CEACAM2. 
Whether CEACAM2 regulates thrombin signaling in platelets remains unclear. 
In response to thrombin (at 0.25-1.0 U/mL), Cc2
–/–
 platelets had comparable 
amplitude and slope of thrombin-mediated aggregation response compared to wild-
type platelets (Figure 2B). In addition, GPCR platelet aggregation mediated by 
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ADP, thrombin and PAR-4 agonist peptide were comparable in Cc2
–/–
 and wild-type 
platelets (Figure 2). While these results would argue against CEACAM2 regulating 
thrombin signaling, more studies using thrombin at sub-threshold concentrations are 
needed to fully address this question.  Moreover, the laser injury model used in this 
study is mediated by thrombin:tissue factor inflammatory process and the Cc2
–/–
 
arterioles had increased thrombi that were more stable under these conditions 
(Figure 7B). Thus, more studies are needed to investigate whether CEACAM2 
affects thrombin signaling pathway. 
Unlike human platelets, murine platelets lack the low-affinity IgG receptor, 
FcgammaRIIa, but contain two ITAM-bearing receptors, GPVI/FcR gamma chain 
and CLEC-2. CEACAM2 also negatively regulates signaling of CLEC-2, which has 
been shown to play a role in thrombus stabilization [40]. Based on our in vivo mouse 
thrombus models, we show that Cc2
–/–
 arterioles have larger thrombi that are more 
stable in response to type I collagen exposure (i.e: ferric chloride induced vascular 
injury of mesenteric arterioles; Figure 7A) and thrombin-driven processes without 
type I collagen exposure (i.e: laser induced injury of cremaster muscle arterioles [41, 
42]; Figure 7B). This was also the case for Cc1
–/–
 (in this study) and PECAM-1
–/–
 
arterioles [43]. While GPVI depletion resulted in the reversal of thrombus growth, 
thrombus stability was less affected, indicating the involvement of other potential 
mechanisms regulating thrombus stability (Figure 7C). 
In conclusion, this study demonstrates the presence of a new ITIM-bearing 
receptor, CEACAM2 (predominantly CC2-2L), in murine platelets that negatively 
regulates collagen GPVI and CLEC-2 signaling in addition to thrombus growth and 
stability in vitro and in vivo. Like CEACAM1, CEACAM2 limits thrombi formation 
under conditions of type I collagen exposure, such as atherosclerotic plaque rupture. 
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Further studies are required to decipher other mechanisms of its role in platelet 
function, thrombus stabilization and wound healing. 
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Figure Legends 
Figure 1. CEACAM2 is expressed on the surface and in intracellular pools in 
murine platelets. 
(A)  Flow cytometric analysis of CEACAM2 surface and total expression on resting 
murine platelets. Platelets were stained with a polyclonal anti-murine CEACAM2 
2052 antibody followed by a secondary PE conjugated anti-rabbit antibody. Normal 
rabbit serum was included as a negative control. For total expression, platelets were 
resuspended in 0.1% (w/v) saponin, and then washed with combination of 0.1% 
(w/v) saponin and 0.2% (w/v) Bovine serum Albumin (BSA). Data were collected 
by a live platelet gate based on forward versus side scatter profiles on a FACS Canto 
II flow cytometer. Results are cumulative data derived from four independent 
experiments and represented as mean fluorescence intensity (MFI) ± SEM 
(**P<0.01; n=4). 
(B)  CEACAM2 surface expression upon agonist stimulation of murine platelets 
using thrombin (0.125-1.0 U/mL), PAR-4 agonist peptide (100-300 µM) and 
collagen related peptide (CRP; 1.0-4.0 µg/mL) over a dose-dependent range 
(**P<0.01 and ***P<0.001; n=4). CEACAM2 surface expression was determined 
as described in A. 
(C) Platelet lysates from wild type and Cc2
–/–
 mice were analyzed by 10% SDS-
PAGE and Western blotting using 1:2000 of rabbit anti–mouse CEACAM2 
polyclonal antibody (2052) (upper panel), followed by reprobing with GAPDH 
antibody to control for protein loading (bottom panel). A ~52 kDa band representing 
CEACAM2 and another one (band X) at ~95kDa representing an unidentified 
protein were detected.  
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 (D)  Flow cytometric analysis of PECAM-1, CEACAM1 and CEACAM2 
expression on resting wild-type versus Cc2
–/–
 platelets. Wild-type and Cc2
–/–
 
platelets were stained with a monoclonal anti-murine PECAM-1 antibody, 
polyclonal anti-murine CEACAM1 2457 antibody or polyclonal anti-murine 
CEACAM2 2052 antibody followed by a secondary PE conjugated anti-rat or anti-
rabbit antibody. Normal rabbit serum (NRS) and isotype control antibody CD3 were 
included as negative controls. Data were collected by a live platelet gate based on 
forward versus side scatter profiles on a FACS Canto II flow cytometer. Results are 
cumulative data derived from four independent experiments and represented as 
mean fluorescence intensity (MFI) ± SEM (**P<0.01; n=4). 
(E)  Cell surface expression of platelet glycoproteins was monitored by flow 
cytometry using specific monoclonal antibodies for wild-type and Cc2
–/–
 platelets. 
Platelets were pre-incubated with anti-mouse integrin β3, CD61 (10 µg/mL), anti-
mouse integrin α2β1, CD49b (15 µg/mL), anti-mouse GPIbα/IX/V, CD42b (10 
µg/mL), and anti-mouse CD44 (10 µg/mL) anti-mouse GPVI (10 µg/mL) and anti-
mouse CD9 (10 µg/mL).  Mean fluorescence intensity (MFI) was reported with a 
standard error of mean for at least four independent experiments and no significant 
difference demonstrated. 
(F) Total expression of platelet glycoproteins on resting wild-type and Cc2
–/–
 murine 
platelets was determined as described in panel A. Antibodies concentrations were 
described in panel E. 
(G) Cell surface expression of CEACAM1 upon agonist stimulation of wild-type 
versus Cc2
–/–
 murine platelets was determined as described in panel B. 
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Figure 2. Cc2
–/–
 platelets are hyper-responsive to stimulation with type I 
collagen, GPVI and CLEC-2-selective agonists, CRP and Rhod.  
(A)  Aggregation responses of PRP (platelet count adjusted to 1x10
8
/mL) for wild-
type (+/+) and Cc2
–/–
 mice were determined following stimulation with the 
following agonists:  (a-c) PAR-4 agonist peptide (125-500 µM), (d-f) ADP (2.5-10 
µM), (g-i) calcium ionophore (1.25-5 µg/mL), (j-l) type I collagen (1.25-5 µg/mL), 
(m-o) CRP (0.625-2.5 µg/mL) and (p-r) Rhod (0.12-0.48 µg/mL). Note that Cc2
–/–
 
platelets are hyper-responsive to stimulation by type I collagen, GPVI and CLEC-2-
selective agonists, CRP and Rhod. These data are representative of at least four 
independent experiments performed. 
(B)  Aggregation responses of washed platelets for wild-type and Cc2
–/–
 mice were 
determined following stimulation with the following agonists:  Thrombin (0.25-1 
U/mL), PAR-4 agonist peptide (250-500 µM), and CRP (5-10 µg/mL). Note that 
Cc2
–/–
 platelets are hyper-responsive to stimulation by GPVI-selective agonist, CRP. 
Figure 3. Cc2
–/–
 platelets display enhanced alpha and dense granule release 
following stimulation with GPVI and CLEC-2-selective agonists, CRP and 
Rhod. 
(A)  Surface expression of P-selectin as a marker of alpha granule release was 
determined for washed platelets stimulated by several agonists. (A.a) Thrombin 
(0.125-0.25 U/mL), PAR-4 agonist peptide (100-300 µM). (A.b) CRP (0.5-2.0 
µg/mL) and (A.c) Rhod (0.6-1.2 µg/mL) and then stained with either a buffer 
control and FITC-conjugated P-selectin mAb for both wild-type, Cc1
–/– 
and Cc2
–/–
 
platelets. FITC-labeled samples were analyzed on a FACS Canto II flow cytometer. 
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Results are representative of three independent experiments (*P<0.05 and 
**P<0.01; n=4). 
(B)  Platelet dense granule exocytosis measured by release of fluorescent quinacrine 
by flow cytometry. Washed platelets (1x10
8
/mL) were derived from both wild-type 
and Cc2
–/–
 mice were stimulated with either no agonist or agonist.  (B.a) Thrombin 
(0.125-1.0 U/mL) or PAR-4 agonist peptide (100-300 µM) or (B.b) CRP (0.25-4.0 
µg/mL). (B.c) Wild-type, Cc1
–/– 
and Cc2
–/–
 platelets were stimulated by Rhod (0.4-
1.2 µg/mL). Samples were analyzed on a FACS Canto II flow cytometer. Data are 
reported as percentage quinacrine release and are representative of four independent 
experiments (*P<0.05, **P<0.01 and ***P<0.001; n=4). 
Figure 4. Cc2
–/–
 platelets display enhanced static adhesion on immobilized type 
I collagen. 
Time course of wild-type and Cc2
–/–
 platelet adhesion to either buffer control or type 
I collagen (50 µg/mL) in the absence of magnesium for 15, 30, 45 and 60 minutes at 
37
o
C. Non-adherent platelets were removed and adherent platelets were measured as 
described in Materials and Methods. Data represents four independent experiments. 
Note that Cc2
–/–
 platelets show a higher level of platelet adhesion to type I fibrillar 
collagen than wild-type platelets (+/+) at all time points (*P<0.05, **P<0.01, 
***P<0.001; n=4). 
Figure 5. Cc2
–/–
 platelets show hyper-phosphorylated proteins after GPVI and 
CLEC-2-selective agonists, CRP and Rhod stimulation over time.  
(A)  Platelets (3x10
8
/mL) from wild-type and Cc2
–/–
 mice were stimulated with 10 
µg/mL of CRP at 37 °C for 3 minutes. Platelet lysate of 30 µg was then loaded onto 
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a 10% (w/v) SDS-PAGE gel. Then Western blotting was performed to measure 
tyrosine phosphorylation, using 1:5000 of HRP-conjugated anti-phosphotyrosine 
RC20 antibody. A protein loading control (bottom panel) blot was stripped and re-
probed using anti-Erk-1/2 Ab for detection of Erk-1 and 2 antigens. The data shown 
are a representative blot of similar results for 3 independent experiments. 
(B) Tyrosine phosphorylation of PLCγ2, Src and Syk was detected from platelet 
lysate after stimulation with 10 µg/mL of CRP versus resting at time 0 and 90 
seconds. Immunoprecipitation of PLCγ2, Src and Syk from platelet lysates was 
performed followed by immunoblotting to detect a. p-PLCγ2, using 1:5000 of a 
HRP-conjugated anti-phosphotyrosine RC20 antibody. b. p-Src, using 1:2000 of 
anti-phospho Src and 1:20,000 of anti-rabbit. c. p-Syk, using 1:20,000 of a HRP-
conjugated anti-phosphotyrosine 4G10 antibody. PLCγ2, Src and Syk antigens 
(bottom panel; a-c), loading control were confirmed by re-probing with a polyclonal 
anti-PLCγ2, anti-Src and anti-Syk antibodies, respectively. The relative intensity of 
tyrosine phosphorelated PLCγ2, Src and Syk was quantified by ImageJ software 
Version 1.46r. The data shown are a representative blot of similar results for 3 
independent experiments. 
(C) Tyrosine phosphorylation of PLCγ2 and Syk was detected from platelet lysate 
after stimulation with 1.2 µg/mL of Rhod versus resting at time 0 and 90 seconds as 
described in panel B. 
Figure 6. Cc2
–/–
 platelets display greater adhesion and thrombus formation 
under arterial flow on immobilized type I collagen. 
(A-C) Rhodamine-labeled whole blood of wild-type and Cc2
–/–
 mice was perfused 
over 500 µg/mL type I fibrillar collagen-coated µ-slide III
0.1 
at a shear wall flow rate 
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of 1800 seconds
-1
. Z-stack images were recorded over 4 minutes with a Zeiss 
Axiovert microscope captured with Axiocam MRm camera and analyzed using 
Zeiss Axiovision Rel4.6 software. Thrombi formed were analyzed by deconvolution 
and 3D reconstructions.  
(A)  Images of in vitro thrombus formation under arterial flow on immobilized type 
I fibrillar collagen for both wild-type and Cc2
–/–
 platelets over 4 minutes. (B)  
Kinetics of thrombus volume (µm
3
) over time was derived by multiplying thrombus 
area (µm
2
) with thrombus height (µm) for both wild-type and Cc2
–/–
 platelets 
(30480±3822 vs 12480±588.2 µm
3
; ***P<0.001; at 4 minutes; n=10). (C) Thrombus 
volume (µm
3
) data from panel B was stratified according to sex, male and female for 
both wild-type and Cc2
–/–
 platelets at the 4 minutes time point (*P<0.05; 
n=5/group). 
Figure 7. Cc2
–/–
 mice display larger and more stable thrombi in vivo.  
(A.a) Z-stack thrombus formation images of FeCl3-induced vascular injury was 
monitored in arterioles of wild-type versus Cc2
–/–
 mice over 10 minutes. The 
different lengths of time after FeCl3 application are specified. Note that thrombi are 
larger in Cc2
–/–
 arterioles over time compared to wild-type control arterioles (n=30). 
(A.b) Quantitative analysis of arterial thrombogenesis of wild-type (●) versus Cc2–/– 
(■) arterioles. Cc2–/– arterioles displayed a significantly larger thrombus volume at 
10 minutes compared to wild-type arterioles (166900±7601 vs 120500±2390 µm
3
; 
***P<0.0001; n=30). 
(A.c) The kinetics of thrombus volume of wild-type versus Cc2
–/–
 arterioles over 
time was reliably measured. Cc2
–/–
 arterioles was significantly increased at 4-10 
minutes compared to wild-type arterioles. 
31 
 
(A.d) The thrombus stability was scored from 1 to 10, with 1 being 0% to 10% 
occupancy and 10 being 91% to 100% occupancy (i.e. complete vessel occlusion) 
visualized over time. Cc2
–/–
 arterioles showed greater stability in thrombi formed 
(7.267±0.143 vs 3.493±0.136; ***P<0.0001; n=30). 
(B.a-b) Platelet thrombus formation in response to laser induced injury in wild-type, 
Cc1
–/–
 and Cc2
–/–
 arterioles. Thrombus volume in Cc2
–/–
 and Cc1
–/–
 arterioles was 
significantly greater than wild-type arterioles (37355±702.6 vs 31956±785.1 vs 
15578±543.7, respectively; ***P<0.0001; n=30) and displayed greater stability in 
thrombi formed (5.733±0.143 vs 4.80±0.010 vs 2.967±0.0894, respectively; 
***P<0.0001; n=30). 
(C.a-b) Thrombus formation in response to FeCl3 after inhibition of mouse GPVI 
with specific monoclonal antibody (mAb) JAQ1 administration to wild-type and 
Cc2
–/–
  mice compared with control IgG-treated wild-type and Cc2
–/–
 or untreated 
wild-type and Cc2
–/–
 mice. Compared with untreated Cc2
–/–
 or control IgG-treated 
Cc2
–/–
 arterioles, JAQ1-treated Cc2
–/–
 arterioles displayed around 2-fold smaller 
thrombus volume at 10 minutes (154300±4741 vs 144600±6613 vs 70050±5077 
µm
3
, respectively; ***P<0.0001; n=10 arterioles from 3 mice/group) and around 2-
fold lower stability score at 10 minutes (7.500±0.166 vs 7.400±0.371 vs 
4.800±0.359, respectively; ***P<0.0001; n=10 arterioles from 3 mice/group). In 
contrast, compared with untreated wild-type or control IgG-treated wild-type 
arterioles, JAQ1-treated wild-type arterioles displayed around 3-fold smaller 
thrombus volume at 10 minutes (118700±5102 vs 109800±4497 vs 55080±5269 
µm
3
, respectively; ***P<0.0001; n=10 arterioles from 3 mice/group) and a 
moderately lower stability score at 10 minutes (4.100±0.100 vs 4.600±0.163 vs 
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3.300±0.213, respectively; **P<0.01; n=10 arterioles from 3 mice/group). 
Supplemental Figure 1. Chromosomal mapping of CEACAM1 and CEACAM2 
genes. 
C57BL/6 splenocytes were cultured and harvested according to standard cytogenetic 
procedures.  DNA was labelled by Nick Translation and Cc1 and Cc2 specific 
probes were labelled with Spectrum green and Spectrum orange, respectively. A) 
Representative FISH analysis of at least 20 metaphases and B) Representative 
karyotype showing the close location of Cc1 (green) and Cc2 (orange) loci on 
chromosome 7 (Band B1).   
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Table 1. Summary of peripheral blood hematologic parameters for wild-type 
and Cc2
–/–
 mice 
Hematologic parameter Wild-type 
(n = 6) 
Cc2
–/–
  
(n = 6) 
WBC, ×10
9
/L 6.20 ± 1.03 5.25 ± 0.66 
RBC, ×10
12
/L 9.07 ± 0.22 8.89 ± 0.46 
HGB, g/L 132.33 ± 3.08 129.33 ± 6.90 
PCV, L/L 0.43 ± 0.01 0.42 ± 0.02 
MCV, fl 48.33 ± 0.55 48.00 ± 0.85 
MCH, pg 14.61 ± 0.24 14.56 ± 0.23 
MCHC, ×10
3
 g/L 302.00 ± 3.40 303.83 ± 3.21 
RDW, % 13.25 ± 0.18 13.58 ± 0.19 
PLT, ×10
9
/L 726.66 ± 23.10 741.00 ± 9.80 
WBC/Neut/, % 8.58 ± 1.72 7.41 ± 1.50 
WBC/Lymph, % 88.91 ± 2.34 90.00 ± 2.27 
WBC/Mono, % 2.50 ± 0.65 3.08 ± 1.26 
WBC/Neut, ×10
9
/L 0.55 ± 0.17 0.37 ±  0.07 
WBC/Lymph, ×10
9
/L 5.47 ± 0.88 4.74 ± 0.65 
WBC/Mono, ×10
9
/L 0.17 ± 0.06 0.16 ± 0.07 
  
 Hematologic parameters were analyzed from wild-type and Cc2
–/–
 whole 
blood. WBC stands for white blood cell; RBC, red blood cell; Hgb, hemoglobin; 
PCV, packed cell volume; MCV, mean cell volume; MCH, mean cell hemoglobin; 
MCHC, mean cell hemoglobin concentration; PLT, platelets; Neut, neutrophils; 
Lymph, lymphocytes; and Mono, monocytes. The assays were run in triplicates, and 
the data shown are representative of 6 independent experiments, and presented as 
MFI ± SEM (P> 0.05 is non-significant for all hematologic parameters), using 
statistics Student t- test. 
 
34 
 
 
